Aspirin use and risk of cholangiocarcinoma: External validation with big data.

Haider Altaii, Sadeer G Al-Kindi, Guilherme H Oliveira, Zaid Yaqoob, Carlos Romero-Marrero

Abstract readLetterComment

In one paragraph

Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort.JAMA oncology · 2020
Observational
Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.EBioMedicine · 2019
Article
Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis.Cancer management and research · 2018
Article
Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014-2019).Annals of gastroenterology
Article

4 · The record

Corrections and comments

Commented on by
Reply.2017
Comment on
Aspirin use and the risk of cholangiocarcinoma.2016

5 · Who and what money

Authors and funding

5 authors.

Haider AltaiiDepartment of Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH.

Sadeer G Al-KindiOncocardiology Program, Harrington Heart and Vascular Institute, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH.

Guilherme H OliveiraOncocardiology Program, Harrington Heart and Vascular Institute, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH.

Zaid YaqoobRespiratory Institute, Cleveland Clinic, Cleveland, OH.

Carlos Romero-MarreroDepartment of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AspirinCholangiocarcinomaBile Duct NeoplasmsBile Ducts, IntrahepaticHumansAspirin

Identifiers

PMID28052348

DOI10.1002/hep.28920

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.